Dysferlinopathy in Tunisia: clinical spectrum, genetic background and prognostic profile
Neuromuscular Disorders · 2023
DOI: 10.1016/j.nmd.2023.08.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuromuscular Disorders, 2023. Verfasst von Ikhlass Belhassen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Neurogenetics, Parkinson's Disease and Cerebrovascular Disease (LR-12-SP-19), Habib Bourguiba University Hospital, University of Sfax, …. Hauptthemen laut MEDLINE: Muscular Dystrophies, Limb-Girdle, Distal Myopathies. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 63 Literaturangaben.
Abstract (Originalsprache)
Dysferlinopathy is a rare group of hereditary muscular dystrophy with an autosomal recessive mode of inheritance caused by a mutation in the DYSF gene. It encodes for the dysferlin protein, which has a crucial role in multiple cellular processes, including muscle fiber membrane repair. This deficit has heterogeneous clinical presentations. In this study, we collected 20 Tunisian patients with a sex ratio of 1 and a median age of 50.5 years old (Interquartile range (IQR) = [36,5-54,75]). They were followed for periods ranging from 5 to 48 years. The median age at onset was 17 years old (IQR = [16,8-28,4]). Five major phenotypes were identified: Limb-girdle muscular dystrophy (LGMDR2) (35%), a proximodistal phenotype (35%), Miyoshi myopathy (10%), Distal myopathy with anterior tibial onset (DMAT) (10%), and asymptomatic HyperCKemia (10%). At the last evaluation, more than half of patients (55%) were on wheelchair. Loss of ambulation occurred generally during the fourth decade. After 20 years of disease progression, two patients with a proximodistal phenotype (10%) developed dilated cardiomyopathy and mitral valve regurgitation. Restrictive respiratory syndrome was observed in three patients (DMAT: 1 patient, proximodistal phenotype: 1 patient, LGMDR2: 1 patient). Genetic study disclosed five mutations. We observed clinical heterogeneity between families and even within the same family. Disease progression was mainly slow to intermediate regardless of the phenotype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Neurogenetics, Parkinson's Disease and Cerebrovascular Disease (LR-12-SP-19), Habib Bourguiba University Hospital, University of Sfax, Tunisia.
- Laboratory of Neurogenetics, Parkinson's Disease and Cerebrovascular Disease (LR-12-SP-19), Habib Bourguiba University Hospital, University of Sfax, Tunisia; Department of Neurology, Habib Bourguiba University Hospital,…
- Department of Neurology, Habib Bourguiba University Hospital, Faculty of Medicine of Sfax, Sfax, Tunisia.
- Pathology Laboratory, Habib Bourguiba University Hospital, Sfax, Tunisia.
- Laboratory of Neurogenetics, Parkinson's Disease and Cerebrovascular Disease (LR-12-SP-19), Habib Bourguiba University Hospital, University of Sfax, Tunisia; Clinical Investigation Center, Habib Bourguiba University Hos…
- U955-IMRB, Team 10: Biology of the Neuromuscular System, Inserm, UPEC, Créteil, France.
Zitieren
APA
Belhassen, I., Laroussi, S., Sakka, S., Rekik, S., Lahkim, L., Dammak, M., Authier, F. J., & Mhiri, C. (2023). Dysferlinopathy in Tunisia: clinical spectrum, genetic background and prognostic profile. Neuromuscular Disorders. https://doi.org/10.1016/j.nmd.2023.08.007
Vancouver
Belhassen I, Laroussi S, Sakka S, Rekik S, Lahkim L, Dammak M, et al. Dysferlinopathy in Tunisia: clinical spectrum, genetic background and prognostic profile. Neuromuscular Disorders. 2023. doi:10.1016/j.nmd.2023.08.007
BibTeX
@article{Belhassen2023,
author = {Belhassen, Ikhlass and Laroussi, Sirine and Sakka, Salma and Rekik, Sabrine and Lahkim, Laila and Dammak, Mariem and Authier, François Jerome and Mhiri, Chokri},
title = {Dysferlinopathy in Tunisia: clinical spectrum, genetic background and prognostic profile},
journal = {Neuromuscular Disorders},
year = {2023},
doi = {10.1016/j.nmd.2023.08.007}
}
EUVIMED